Advertisement

Related Videos

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

David A. Hyman, MD, JD, on Inclusive Shared Savings

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Advertisement

Advertisement




May
20
Today In Oncology
AI Avatar–Based Education Leads to Improved Patient Understanding of Radiation Treatment Plans
Novel Gene Fusion Detector for Pediatric B-ALL Shows High Sensitivity
ASCENDE-RT 15-Year Update Shows No Overall Survival Benefit, With ‘Borderline’ Signal for Fewer Deaths
Study Shows Potential Missing Patient Information in SEER Database
Recurrence With Concurrent or Sequential Radiation Dose Escalation to the Surgical Cavity in High-Risk Early Breast Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo